Please login to the form below

Not currently logged in
Email:
Password:

Polyphor appoints new chief medical and development officer

Dr Debra Baker joins the firm from Novartis

Polyphor has appointed Debra Baker as its new chief medical and development officer (CMDO) in a role that focuses on clinical strategy and drug development.

Dr Baker arrives at Polyphor from Novartis, where she held several positions including global head of medical affairs, development head for infectious diseases, transplants and immunology, and global head of clinical operations and services.

She said: “it is an exciting time to join Polyphor and I am very eager to share my experience in drug development in its mission to help patients.”

Giacomo Di Nepi, CEO at Polyphor, added: “I am very happy Debra joins Polyphor. I had the opportunity of working with her at Novartis and really appreciated her leadership, drive and capabilities. Her expertise is immediately applicable to her new role as CMDO of Polyphor and to our clinical programmes,”

Dr Baker succeeds Leon Hootftman, who leaves Polyphor to take a new position.

17th March 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics